ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 175 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,980,451 | -34.7% | 55,552 | -15.5% | 0.00% | -20.0% |
| Q2 2023 | $3,033,223 | +33.1% | 65,754 | +15.7% | 0.01% | +25.0% |
| Q1 2023 | $2,279,613 | -28.8% | 56,850 | -17.7% | 0.00% | -42.9% |
| Q4 2022 | $3,201,619 | +40.8% | 69,106 | +25.9% | 0.01% | +40.0% |
| Q3 2022 | $2,274,000 | +37.1% | 54,907 | +96.3% | 0.01% | +25.0% |
| Q2 2022 | $1,659,000 | -12.3% | 27,969 | +7.3% | 0.00% | 0.0% |
| Q1 2022 | $1,891,000 | +490.9% | 26,070 | +585.5% | 0.00% | +300.0% |
| Q4 2021 | $320,000 | -83.9% | 3,803 | -74.2% | 0.00% | -80.0% |
| Q1 2021 | $1,984,000 | -2.5% | 14,737 | -0.1% | 0.01% | 0.0% |
| Q4 2020 | $2,035,000 | +7.4% | 14,757 | -36.0% | 0.01% | 0.0% |
| Q3 2020 | $1,895,000 | -30.4% | 23,060 | -33.7% | 0.01% | -37.5% |
| Q2 2020 | $2,721,000 | +54.5% | 34,787 | -12.2% | 0.01% | +33.3% |
| Q1 2020 | $1,761,000 | +17.5% | 39,632 | +12.9% | 0.01% | +50.0% |
| Q4 2019 | $1,499,000 | +56.3% | 35,090 | +56.6% | 0.00% | +100.0% |
| Q3 2019 | $959,000 | -38.8% | 22,406 | -9.2% | 0.00% | -60.0% |
| Q2 2019 | $1,568,000 | +118.4% | 24,686 | +138.4% | 0.01% | +150.0% |
| Q1 2019 | $718,000 | – | 10,355 | +172483.3% | 0.00% | – |
| Q2 2018 | $0 | – | 6 | -33.3% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 9 | -99.6% | 0.00% | – |
| Q4 2017 | $115,000 | +6.5% | 2,483 | +22.4% | 0.00% | – |
| Q3 2017 | $108,000 | -13.6% | 2,029 | +1.1% | 0.00% | – |
| Q2 2017 | $125,000 | +92.3% | 2,007 | +117.0% | 0.00% | – |
| Q4 2016 | $65,000 | -20.7% | 925 | -19.6% | 0.00% | – |
| Q3 2016 | $82,000 | +74.5% | 1,151 | +18.7% | 0.00% | – |
| Q2 2016 | $47,000 | +6.8% | 970 | +39.0% | 0.00% | – |
| Q1 2016 | $44,000 | +388.9% | 698 | +843.2% | 0.00% | – |
| Q4 2015 | $9,000 | -99.5% | 74 | -99.6% | 0.00% | -100.0% |
| Q3 2015 | $1,985,000 | +415.6% | 20,608 | +447.4% | 0.02% | +500.0% |
| Q2 2015 | $385,000 | +70.4% | 3,765 | +3.3% | 0.00% | +50.0% |
| Q1 2015 | $226,000 | – | 3,645 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |